Evidence map›Paper›PMID 35677614›Full record

ArticleSTAR protocols2022

Luciferase assay system to monitor fibroblast growth factor signal disruption in human iPSCs.

Seiya Kanno, Kashu Mizota, Yusuke Okubo, Tatsuto Kageyama, Lei Yan, Junji Fukuda

Open access · goldAbstract read
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Seiya KannoFaculty of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya Ward, Yokohama, Kanagawa 240-8501, Japan.
Kashu MizotaFaculty of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya Ward, Yokohama, Kanagawa 240-8501, Japan.
Yusuke OkuboDivision of Cellular & Molecular Toxicology, Center for Biological Safety & Research, National Institute of Health Sciences, 3-25-26 Tono-machi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.
Tatsuto KageyamaFaculty of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya Ward, Yokohama, Kanagawa 240-8501, Japan.
Lei YanFaculty of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya Ward, Yokohama, Kanagawa 240-8501, Japan.
Junji FukudaFaculty of Engineering, Yokohama National University, 79-5 Tokiwadai, Hodogaya Ward, Yokohama, Kanagawa 240-8501, Japan.
Yokohama National University · JPNational Institute of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a protocol for a live-cell luciferase assay system for continuously monitoring fibroblast growth factor (FGF) signal disruption in human-induced pluripotent stem cells (iPSCs). Signal disrupting effects of chemicals are used as an indicator to evaluate toxicity. The assay is reliably predictive of the effects of limb malformation chemicals (AUC = 0.93). The current approach is limited to FGF signal disruption, and combinations with other types of signaling will be required to detect the effects of different toxicants. For complete details on the use and execution of this protocol, please refer to Kanno et al. (2022a).

Indexed as

Induced Pluripotent Stem CellsFibroblast Growth FactorsHumansLuciferasesSignal TransductionFibroblast Growth FactorsLuciferasesBiotechnology and bioengineeringCell-based AssaysCell BiologyCRISPRMolecular BiologyStem Cells

Identifiers

PMID35677614
PMCPMC9168156
OpenAlexW4281754536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.